Medication info
Hanwha Rocan Tablet 10/8 Milligrams (Rosuvastatin Calcium, Candesartan Cilexetil)

Hanwha Rocan Tablet 10/8 Milligrams (Rosuvastatin Calcium, Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Hanwha Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 202301658 · Approved 2023.05.24 · Insurance code 651602910

Summary

Main use
Treatment of dyslipidemia, hypertension, and heart failure; suppression of atherosclerosis progression and reduction of cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Hanwha Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, hypertension, and heart failure; suppression of atherosclerosis progression and reduction of cardiovascular disease risk

  • Essential hypertension
  • impaired left ventricular contractile function
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
View approved original text

This medication is used for patients who need to take both Candesartan Cilexetil and Rosuvastatin simultaneously. Candesartan Cilexetil is applicable in patients with essential hypertension or heart failure, particularly those with impaired left ventricular contractile function, and in cases where ACE inhibitor therapy is insufficient or poorly tolerated. Rosuvastatin is used for hypercholesterolemia, particularly for primary and familial hypercholesterolemia, as well as for mixed dyslipidemia, and serves as an adjunctive treatment when dietary control is difficult. Additionally, Rosuvastatin helps to slow the progression of atherosclerosis and reduce the risk of cardiovascular diseases. This medication is effective in managing both hypertension and dyslipidemia together to improve cardiovascular health.

How to take

Adult dose

This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication may cause serious harm to the fetus when taken during pregnancy, particularly in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergic reactions to this medication, severely impaired liver function, pregnant or nursing women, and those with muscle disorders should not take this medication. Elderly patients or those with mildly impaired liver function, elevated blood potassium levels, or existing cardiovascular disease should take this medication with caution, and regular blood tests and health checks are necessary. This medication may cause muscle-related side effects such as myalgia, myopathy, and rarely rhabdomyolysis; thus, if muscle pain or weakness occurs during use, a doctor should be consulted immediately. Liver function abnormalities may occur, so liver function tests should be conducted regularly before and during treatment, and the medication should be stopped if liver enzyme levels rise significantly. As this medication lowers blood pressure, symptoms of hypotension or dizziness may occur, necessitating caution while driving or operating machinery. Drug interactions may occur, so inform the doctor or pharmacist of any other medications currently being taken. This medication is not recommended for children as its safety and efficacy have not been established. In case of overdose, symptoms may include hypotension or dizziness; seek medical attention immediately for appropriate treatment. Store this medication out of reach of children and avoid transferring it to other containers.

Side effects

Headaches, nasopharyngitis, localized infections, chest discomfort, fatigue, inflammation, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, nausea, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, tooth extraction, position-related dizziness, chalazion, periodontitis, musculoskeletal pain, neck pain, cataracts, increased blood pressure, orthostatic hypotension, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, bruising, unstable angina, idiopathic pulmonary fibrosis, wet cough, exacerbation of hypertension, unstable blood pressure, dizziness, adrenal insufficiency, angioedema, dizziness, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, cognitive impairment, sexual dysfunction, gynecomastia, liver failure, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, dry mouth, sleep disorders, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, hypersensitivity reactions including angioedema, constipation, nausea, abdominal pain, itching, rash and urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, headache, dizziness, dyspepsia, gastroenteritis, tachycardia, palpitations, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, somnolence, rash, increased sweating, hematuria, hypoglycemia, nephrolithiasis, cough, tooth extraction, increased ALT, increased CK, increased AST, asthenia, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, acute renal failure, shock, syncope, loss of consciousness, hypotension, tachycardia, dizziness, headache, asthenia, fever, sensory abnormalities, low back pain, joint pain, proteinuria, increased serum potassium, increased serum creatinine, decreased serum sodium, elevated liver enzymes, jaundice, hepatitis, angioedema, rhabdomyolysis, myalgia, myopathy, myositis, immune-mediated myopathy, muscular weakness, ocular muscle weakness, interstitial lung disease, liver failure, cognitive impairment, memory decline, forgetfulness, amnesia, memory disorders, confusion, severe muscular weakness, ocular muscle weakness, dizziness due to hypotension, fatigue, intestinal vasodilation, abdominal pain, nausea, vomiting, diarrhea, acute renal failure, musculoskeletal toxicity, myalgia, myopathy, rhabdomyolysis, increased CK levels, elevated transaminases, increased ALT, increased AST, elevated γ-GTP, liver dysfunction, jaundice, rash, urticaria, itching, angioedema, rhabdomyolysis, myalgia, asthenia, increased CK, elevated serum and urinary myoglobin levels, joint pain, myalgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, fever, relief, dyspnea, abnormal chest X-ray findings, shock, syncope, loss of consciousness, syncope due to hypotension, loss of consciousness, hypotension, blood pressure drop, increased serum potassium, increased serum creatinine, decreased serum sodium, elevated liver enzymes, jaundice, hepatitis, angioedema, rhabdomyolysis, myalgia, myopathy, myositis, immune-mediated myopathy, muscular weakness, ocular muscle weakness, interstitial lung disease, liver failure, cognitive impairment, memory decline, forgetfulness, amnesia, memory disorders, confusion, severe muscular weakness, ocular muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 to 30 degrees Celsius (room temperature). This way, the effectiveness of the medication is well maintained and can be safely used.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.